Allt inom Regulatory
Nanexa publishes year-end report and Q4 report 2024
The clinical Phase I study conducted in the NEX-22 project with good results and focus on the evaluation with Novo Nordisk has provided a good starting point for 2025.
Nomination Committee for the 2025 Annual General Meeting in Nanexa AB (publ)
The Nomination Committee for the Annual General Meeting 2025 in Nanexa AB (publ) has been appointed.